Fintech

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Globenewswire·April 2, 2026 at 11:30 AM

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data...

Original Source

Globenewswire — www.globenewswire.com

Related in Fintech

DOJ crypto memo author named interim AG
CoinDesk
Drift crypto exchange remains frozen after attack
PYMNTS
Amazon adds fuel surcharge for sellers
PYMNTS
DOJ Appeals Anthropic AI Ban Restoration
PYMNTS

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

DOJ crypto memo author named interim AG

Drift crypto exchange remains frozen after attack

Amazon adds fuel surcharge for sellers

DOJ Appeals Anthropic AI Ban Restoration